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Structure-based drug designhe selective active transport of ions like H+, Na+, K+, Ca2+, Zn2+, and Cu2+
across diverse biologicalmembrane systems.Manymembers of the P-type ATPase protein family, such as the
Na+,K+-, H+,K+-, Ca2+-, and H+-ATPases, are involved in the development of pathophysiological conditions or
provide critical function to pathogens. Therefore, they seem to be promising targets for future drugs and
novel antifungal agents and herbicides. Here, we review the current knowledge about P-type ATPase
inhibitors and their present use as tools in science, medicine, and biotechnology. Recent structural
information on a variety of P-type ATPase family members signiﬁes that all P-type ATPases can be expected
to share a similar basic structure and a similar basic machinery of ion transport. The ion transport pathway
crossing the membrane lipid bilayer is constructed of two access channels leading from either side of the
membrane to the ion binding sites at a central cavity. The selective opening and closure of the access
channels allows vectorial access/release of ions from the binding sites. Recent structural information along
with new homology modeling of diverse P-type ATPases in complex with known ligands demonstrate that
the most proﬁcient way for the development of efﬁcient and selective drugs is to target their ion transport
pathway.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionMembrane proteins are in general regarded as extremely potent
drug targets due to their role as transporters and mediators in the
interaction of the cell with the surrounding environment, between
cells, and between cellular compartments. This role, and their highly
exposed position in the cell, renders them of utmost importance in
cellular physiology. P-type ATPases form a superfamily of cation
transporters of various biological membranes. These enzymes are
found in all kingdoms of life and pump speciﬁc ions through thePCP, Adenylyl 5′-(beta,gamma-
ydroxybenzene; Br2-TITU, 1,3-
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l rights reserved.lipid bilayer at the expense of one ATP molecule per cycle [1–6].
Thus, P-type ATPases maintain steep electrochemical gradients and
cell homeostasis [1–6]. Sequence motifs deﬁne ﬁve subfamilies, P1
through P5-type ATPases, with further subclassiﬁcations A, B, C, and
D. These classiﬁcations also correlate with speciﬁc transport
activities. P2B pumps for example include the sarco(endo)plasmic
reticulum Ca2+-ATPases.
Maintenance of the proper gradients for essential ions across
cellular membranes makes P-type ATPases crucial for cell survival.
Indeed, Ca2+, Na+, K+, and H+ gradients control numerous secondary
transport processes and impose a stringent regulation on diverse
signaling pathways. Because of their pivotal role, these pumps have
been linked to disorders displaying various degrees of severity. The
Menkes and Wilson diseases arise from mutations in copper-
transporting P1B-type ATPases [7]. Neurodegenerative disorders are
related to mutations in brain Na+,K+-ATPase, such as the migraine
subtype familial hemiplegic migraine type 2 [8] and the movement
disorder familial rapid-onset dystonia parkinsonism [9]. Aggravated
parkinsonism is also linked to mutations within the lysosomal
ATP13A2, a neuronal P5-type ATPase [10]. Mutations in sarcoplasmic
reticulum Ca2+-ATPases (SERCA) isoforms can cause recessive Brody
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proliferation resulting in malignant tumors can also be induced by a
dysfunction of different pumps [12,13] and impairment of SERCA
function has been linked to apoptotic events which are triggered by a
rise in cytoplasmic calcium concentration [14]. P-type ATPases
therefore appear as attractive drug targets in a broad range of
pathologies and pharmacological settings. In this context, the cardiac
Na+,K+-ATPase and the gastric H+,K+-ATPase already have a long
history of therapeutic application. Inhibition of the Na+,K+-ATPase by
cardiotonic steroids is used in the medical treatment of congestive
heart failure [15], whereas inhibition of the gastric H+,K+-ATPase is
part of the treatment of dyspeptic conditions [16]. Other members of
the family are considered as prominent targets for future drug
development. For instance, the inhibition of the human Ca2+-ATPases
by thapsigargin-derived prodrugs has been described as a promising
tool in prostate cancer therapy [17] and fungal H+-ATPases are
regarded as potential targets for the development of novel antifungal
medication and fungicides [18].
An abundant literature is available to describe the mode of action of
each class of inhibitors on their respective target. However, a more
global approach may be required if one aims at expanding the list of
inhibitors to target new categories of pumps. A thorough analysis of the
general mechanisms governing pump inhibition would therefore be
particularly useful to deﬁne common principles applicable to the
selection and design of second generation and newclasses of inhibitors.
In the last couple of years, structural information on diverse P-type
ATPases has emerged with an increasing pace. Crystal structures are
now available for the Ca2+-ATPase in nearly all conformations relating
to the functional cycle [19–24] or as complexeswith inhibitors [27–29],
and the ﬁrst structures of the Na+,K+-ATPase and the H+-ATPase haveFig. 1. Post-Albers scheme of the transport cycle for P-type ATPases. Following this scheme, a
the cell, respectively. The two states represented in boxes correspond to the two cation occ
dashed state corresponds to an occluded state for the Na+,K+-ATPase. Structures of SERCA
general. Inhibitors that are known to target individual forms are indicated for each state (SE
green; inhibitors common to the three pumps in light purple).been determined [25,26]. Most importantly, these structure deter-
minations and insight on conformational changes together with a
wealth of biochemical data have brought valuable information on
how to address the future development of efﬁcient and selective
inhibitors leading theway to newdrugs. In this context, and in light of
the new structures available, the purpose of this review is to compare
the mode of action of different classes of inhibitors and to draw
general conclusions on how pumps are targeted and inhibited.
Finally, perspectives in the application of these general principles to
the design of new inhibitors – in particular for pumps with no
selective inhibitors knownyet such as the fungal H+-ATPases –will be
discussed.
2. General description of P-type ATPases
A hallmark of all P-type ATPases is the formation of a covalent
aspartyl-phosphate intermediate by autophosphorylation of the
pump catalytic subunit on a conserved aspartic residue — a
mechanism which distinguishes them from other ATPases such as F-
or V-type ATPases [2–4]. Many of the P-type ATPases perform two-
way transport, such as the Na+,K+-ATPase and the Ca2+-ATPase (in fact
Ca2+,H+-ATPase). The reaction cycle is traditionally described by the
Post-Albers scheme (Fig. 1) in which the pump oscillates between two
functional states, E1 and E2, related to the direction of the ion
transport, i.e. from the cytosol and into the lumenal/extracellular
environment, and counter-transport into the cytosol, respectively
[5,6]. The ion translocation proceeds through a Ping-Pongmechanism,
cation species being sequentially transferred in opposite directions
across the membrane. The opening and closure of the access channels
are tightly coupled to conformational changes within the cytoplasmicions of species X and b ions of species Y are transported out of and into the cytoplasm of
luded states where the access pathways to both sides of the membrane are closed. The
in the (Ca2)E1P [21], E2P [24] and E2 [78] states are included, representing pumps in
RCA inhibitors in red; Na+,K+-ATPase inhibitors in dark blue; H+,K+-ATPase inhibitors in
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dephosphorylation, and phosphate release from the enzyme. Conse-
quently, ions are successively taken up at ion binding sites from one
side of the lipid bilayer, occluded within the transmembrane domain,
and then released on the other side of the membrane, in exchange for
the second ion species [2–6].
Of the P-type ATPase family, some members have been character-
ized more extensively. The Na+,K+-ATPase, originally discovered in
1957 [30], was the ﬁrst one to be identiﬁed. This house-keeping
enzyme, found in various isoforms and in all animal cells, maintains
proper K+ and Na+ concentrations in the cells. The gradients are vital
for the processes of cell excitability and volume regulation and serve
as a driving force for the secondary transport of ions, sugars, and
amino acids [31,32]. The gastric H+,K+-ATPase is localized in the
plasma membrane of the parietal cells of the gastric mucosa. It is
responsible for the last step of acid secretion by actively exporting
protons into the stomach lumen along with Cl− anions extruded from
conductance channels to form the gastric juice [33]. The Ca2+-ATPase
from sarco(endo)plasmic reticulum (SERCA) is an important regulator
of intracellular calcium concentration. It enables muscle contraction/
relaxation and exerts a general tight control on calcium signaling
pathways whose abnormal regulation can lead to severe pathologies
[34]. Finally, H+-ATPases are responsible for the establishment and
maintenance of the electrochemical gradient across fungal and plant
plasma membranes, and thus play a vital role for secondary active
transport in these organisms, such as the up-take of nutrients [35].
Though serving distinct cellular functions, all these enzymes share a
high degree of resemblance, the Na+,K+-ATPase and the gastric H+,K+-
ATPase being close relatives with a sequence identity of 62% [36].
A huge step in the understanding of the intricate mechanisms
behind ion pumping was made when the ﬁrst atomic structures of the
sarco(endo)plasmic reticulum Ca2+-ATPase from rabbit skeletal mus-
cle were determined [19–21]. These structures revealed the general
architecture of the catalytic subunit of P-type ATPases which
encompasses three cytoplasmic domains — the A (actuator), P
(phosphorylation), and N (nucleotide binding) domains — and a
transmembrane segment of 10 helices (TM1 to TM10) bearing the two
embedded Ca2+ binding sites. At present, nearly all of the functional
states of the SERCA pump (E1·ATP, E1P, E2P, E2·Pi, E2) have been
structurally characterized [19–24] (Fig. 1). More recently, two other
members of the P-type ATPase family have been structurally
described: the pig renal Na+,K+-ATPase in the [Rb2]E2·MgF42− occluded
state, representing the [K2]E2·Pi form [25], and the Arabidopsis
thalianaH+-ATPase in an E1·AMPPCP partially occluded state, probably
representing the protonated E1·ATP state [26]. These structures
enabled a direct comparison between three members of the P-type
ATPase family and shed new light on the general mechanism of cation
transport as well as the speciﬁc properties of each transporter. Indeed,
the H+-ATPase belongs to the subgroup III and displays an auto-
inhibitory mechanism provided by an extended C-terminal regulatory
(R) domain [35] while the Na+,K+-ATPase is one of the few oligomeric
P-type ATPases and performs an electrogenic transport reaction with
an additional Na+ site in the cation binding pocket [37]. These new
structures constitute a valuable source of information for the design of
inhibitors targeting speciﬁc P-type ATPases.
3. Pumps as drug targets
Historically the discovery of drugs for the treatment of diseases has
been based on trial and error principles. A vast number of plant,
animal or mineral products were applied to prevent, diagnose, and
cure illness. Some of them are still used by millions of people and a
few of those ancient drugs are nowadays shown to be inhibitors of the
ion transport systems, pumps included. In the past few decades, the
critical role of P-type ATPases in the regulation of cellular metabolism
attracted special attention to the design of new, highly speciﬁcinhibitors of these proteins. To date, several inhibitory compounds and
families have been characterized for P-type ATPases. Table 1 presents
a list of the most important known inhibitors for the Ca2+-, H+,K+-,
and Na+,K+-ATPases. These molecules display various degrees of
potency and selectivity towards their cellular target. Thapsigargin,
for example, is a highly speciﬁc inhibitor of SERCA Ca2+-ATPase with
an IC50 in the subnanomolar range [38]. On the other hand, Br2-TITU
has a lower potency and binds to both the Ca2+-ATPase and the Na+,
K+-ATPase [39]. Some compounds can also target other cellular
proteins, such as celecoxib, a non-steroidal anti-inﬂammatory agent
originally identiﬁed as a blocker of the cyclo-oxygenase-2 [40]. The
principles of inhibition are quite well understood for the best
characterized inhibitors, in particular for SERCA inhibitors thapsigargin
(TG), cyclopiazonic acid (CPA), and 2,5-di-(t-butyl)-dihydroxybenzene
(BHQ). Indeed, their binding sites on SERCA have been structurally
determined [19–24,27–29]. The detailed mode of action of these
compounds will be described later in this review. However, the precise
blocking mechanism of many of the listed compounds remains elusive.
More biochemical and structural data are needed to acknowledge them
as inhibitors of potential therapeutic value.
3.1. Na+,K+-ATPase inhibitors: keeping the heart beat
Cardiac glycosides, also called cardiotonic steroids (CTS), are well-
known inhibitors of the Na+,K+-ATPase — their only pharmacological
receptor identiﬁed so far. They consist of a steroid core with a lactone
moiety (ﬁve-membered, cardenolides, or six-membered, bufadieno-
lides) attached at position 17 and sugars of different nature and length
at position 3 [41] (see ouabain as an example in Fig. 3C). They are
naturally found in many plants — the common foxglove (Digitalis
purpurea) is, for example, a source of digoxin [42]. Bufadienolides are
also secreted as toxins by a few animals including several species of
toads (Bufo marinus), snakes (Rhabdophis tigrinus), and ﬁreﬂies
(Photinus species) [43]. The use of CTS in the treatment of cardiac
insufﬁciency was ﬁrst introduced by William Withering in 1785 [44],
though some texts suggest that ancient Egyptians were aware of the
curative properties of bufadienolide-containing plants such as squill
and used them to treat heart diseases [45]. The generally accepted
explanation for the positive effect of CTS on the patients heart (the so-
called sodium pump lag hypothesis) suggests the following sequence
of events: Inhibition of the Na+,K+-ATPase by CTS binding to its
extracellular side provokes, at least locally, a raise in intracellular Na+
concentration. As a result, the secondary active transport of Ca2+ out of
the cell is slowed down and contractility of the cardiac muscle is
increased (positive inotropic effect) [46]. This picture became more
complicated a few decades ago when endogenous compounds
exhibiting the same biological activity as exogenous CTS were
identiﬁed in mammals [47]. So far, ﬁve different endogenous CTS
have been chemically characterized and a more complex nature of
their physiological function in mammals slowly emerges [48]. Indeed,
it has recently been postulated that the Na+,K+-ATPase forms a
compartment-speciﬁc receptor complex with the tyrosine kinase Src
which, upon its activation induced by binding of CTS to the pump,
initiates a cascade of phosphorylation events within the cell that
regulate downstream effectors. This signaling pathway does not imply
changes in the intracellular Na+ concentration [49]. Therefore, even at
concentrations far below those used in CTS medication, endogenous
compounds can exert an effect on cell physiology and lead to a large
spectrum of cellular responses including gene activation, motility,
cell–cell contact, cell proliferation or apoptosis [48]. This new role of
the Na+,K+-ATPase as a signal transducer has opened new perspectives
for the development of anti-cancer drugs derived from CTS, notably
for the treatment of breast cancer [13].
In addition to CTS, the pharmacological effects of several other
compounds have been related to their interaction with the Na+,K+-
ATPase. The antipsychotic drug chlorpromazine and the anti-malarial
Table 1
List of known inhibitors of therapeutic interest for the Ca2+-, Na+,K+-, H+,K+-, and H+-ATPases
Class of inhibitor Compounds Type and origin Therapeutical applications
SERCA inhibitors
Thapsigargin and
derivatives [38,84]
Thapsigargin (TG), Boc12-ADT Sesquiterpene lactones from the plant
Thapsia garganica
Prodrugs for prostate cancer therapy
2,5-di-(t-butyl)-
dihydroxybenzene [27]
BHQ Synthetic compound Anti-oxidant agent
Cyclopiazonic acid [28,29,127] CPA Mycotoxin originally isolated from
Penicillium and Aspergillus species
Estrogenic alkylphenols
[71,73,88]
Bisphenol A, Diethylstilbestrol (DES), Tetrabromobisphenol
A (TBBPA), Nonylphenol, Octylphenol, 3,5-dibutyl-4-
hydroxytoluene (BHT)
Estrogenic alkylphenols Toxic effect on testis development
Bisphenol A: plasticizing agent
DES: Artiﬁcial estrogen DES: Therapeutic agent to treat different
gynecological problems and growth
promotant factor in livestock
TBBPA: Brominated Flame Retardant
Paxilline [128] Paxilline Alkaloid mycotoxin from P. paxilli Tremorgenic effect
Macrocyclic lactones [70] Ivremectin, Cyclosporin A, Rapamycin Macrocyclic lactones Immunosuppressant agent, antihelminthic
agent (Ivermectin)
Curcuminoids [74] Curcumin Component of the Indian curry spice
turmeric
Antitumoral, antioxidant, antiarthritic, anti-
amyloid and anti-inﬂammatory agents
Aromatic isothiouronium
derivatives [39]
Br2-TITU
2-aminoethoxy-diphenyl
borate [86]
2-APB
Clotrimazole [129] Clotrimazole Antifungal Antimycotic agent
Celecoxib [71] Celecoxib Non-steroidal drug (Celebrex®) Anti-inﬂammatory drug used in the
treatment of arthritis and acute pain
Chlorpromazine [50] Chlorpromazine (CPZ) Phototoxic antipsychotic drug
Chloroquine [50] Chloroquine (CLQ) Anti-malarial drug
Xestospongin C [87] Xestospongin C Marine alkaloid from the Okinawan
sponge Xestospongia Sp. I
Organo-chlorine pesticides
[130]
Chlordecone, Toxaphene Organo-chlorine pesticides Pesticide
Artemisinin and derivatives
[75]
Artemisinin Sesquiterpene lactones from sweet
wormwood (Artemisia annua)
Anti-malarial drug
Halothane [131] Halothane Volatile anesthetic
Melittin [132] Melittin Amphipathic peptide from bee venom
Na,K-ATPase inhibitors
Cardiotonic Steroids [41,48] Ouabain, Digoxin, Digitoxin, Digoxigenin, Bufalin,
Bufagenin, Strophanthidin, Proscillaridin A
Cardiotonic Steroids Treatment of congestive heart failure and
cardiac arrhythmia
Coumestans [133] PCALC36 Wedelolactone from Eclipta prostrata
Palytoxin [58] Palytoxin (PTX) Marine toxin from Palythoa polyps Tumor promoter
Aromatic isothiouronium
derivatives [55]
Br-TITU, Br2-TITU Aromatic isothiouronium derivatives
Guanidium derivatives [55] pXBG, mXBG Guanidium derivatives
Tetrapropylammonium [56] TPA
Amines [54,57] Ethylenediamine, Bretylium Alkyl or aryl, secondary, tertiary and
quaternary amines
Class III antiarrhythmic drug (Bretylium)
Oligomycin [134] Oligomycin Macrolides from Streptomyces Antibiotic
Chlorpromazine [50] Chlorpromazine (CPZ) Phototoxic antipsychotic drug
Chloroquine [50] Chloroquine (CLQ) Anti-malarial drug
Procaine, Tetracaine and
Dibucaine [51]
Procaine, Tetracaine, Dibucaine Amino-esters Local anesthetics
Gramidicin A [52] Gramidicin A Antibiotic
Melittin [135] Melittin Amphipathic peptide from bee venom
Gastric H,K-ATPase inhibitors
PPIs (Proton Pump Inhibitors)
[59,60]
Omeprazole, Tenatoprazole, CMN 131, Lansoprazole,
Timoprazole, Rabeprazole, Pantoprazole,
Esomeprazole, …
Synthetic compounds Anti-ulcer (duodenal and gastric) agents
PCABs (Potassium-competitive
acid pump antagonists,
formerly APA) [59–62]
SCH28080, BYK 99, Imidazopyridines, YH1885,
MDPQ 2,4-Diaminoquinazoline, soraprazan
Synthetic compounds Anti-ulcer agents
Diterpenoids [63] Scopadulcic Acid B (SA-B), Diacetyl Scopadol (DAS) From the Paraguayan traditional
medicinal herb Scoparia dulcis
Antiviral agent
Cibenzoline [64] Cibenzoline Class I antiarrhythmic agent
Prodigiosins [65] Prodigiosins Antibiotic red pigments produced by
microorganisms including
Streptomyces and Serratia
Antibiotic
Melittin [136] Melittin Amphipathic peptide from bee venom
H-ATPase inhibitors
NEM [137] NEM
Dio-9 [138] Dio-9 Antibiotic
Ebselen [120] Ebselen
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including Ca2+- and Na+,K+-ATPases [50]. Local anesthetics (procaine,
tetracaine, dubucaine) are also affecting the Na+,K+-ATPase pump
activity in a cation-dependentmanner [51]. The antibiotic gramicidin
A, known to form a membrane-spanning channel that selectively
transports monovalent ions such as Na+ and K+ through the lipid
bilayer, has recently been described as a mixed-type inhibitor of the
Na+,K+-ATPase [52]. The antibiotic oligomycin has also been shown to
stabilize E1-occluded states of the pump [53]. The fact that either
these inhibitors are known to interact with other proteins or their
inhibitory effects are observed at high concentrations makes them
however irrelevant from a practical point of view.
Cationic compounds including isothiouronium and guanidinium
derivatives, and different types of amines are also known to block the
Na+,K+-ATPase [54–56]. In particular bretylium, an antiarrhythmic
drug used to treat ventricular tachycardia and ﬁbrillation, is acting as a
K+-antagonist on the Na+,K+-ATPase [57]. Finally, palytoxin constitutes
a unique type of inhibitor of the Na+,K+-ATPase. This marine toxin
produced by coral polyps binds to the extracellular side of the ATPase
and transforms the pump into an ion channel. The fact that palytoxin,
being a speciﬁc inhibitor of the Na+,K+-ATPase, at the same time acts as
a skin tumor promoter, suggests (as in the case of ouabain)
involvement of the ATPase in the process of signal transduction [58].
3.2. Gastric H+,K+-ATPase inhibitors: controlling acid secretion
Gastric diseases are generally not life-threatening but can be quite
painful. The two major pathological disorders associated with
acidiﬁcation of the digestive tract are peptic ulcers, which in 80% of
the cases are caused by Helicobacter pylori infection of the stomach,
and gastroesophageal reﬂux disease (GERD). Since the export of
protons into the stomach lumen by the H+,K+-ATPase constitutes the
last step of acid secretion, inhibition of this gastric pump has now
supplanted all other therapeutic strategies in the treatment of gastric
complications, including the targeting of histamine H2 receptors [59].
The ﬁrst generation of H+,K+-ATPase inhibitors, simply called the
Proton Pump Inhibitors (PPIs), was introduced in the 1970s when
derivatives of a compound termed CMN 131 were shown to have
antisecretory activity. Further development of these compounds led to
the synthesis of omeprazole, ﬁrst commercialized in the late 1980s,
and being now the most commonly used drug to treat peptic ulcers
and GERD [60]. The binding of these benzimidazole derivatives to the
extracellular side of the H+,K+-ATPase is irreversible and requires the
acidiﬁcation of the surrounding environment by active H+-transport to
be activated. Indeed, PPIs must be converted into an active form by
gastric acid before they can react with the cysteines located on the
lumenal surface of the pump. Because of this activating mechanism,
there is a lag time in the cellular response to PPI absorption and the
pain relief is consequently delayed. For this reason, new types of
inhibitors which would be fast-acting and acid-independent have
been sought. In the 1980s, the imidazopyridine SCH28080 was found
to display the same antisecretory properties as PPIs even at higher pH
values [61]. Several tertiary amines derived from SCH28080 were
subsequently synthesized to gain in activity and bypass the side
effects observed with this ﬁrst compound. A new class of inhibitors
was born: the Potassium-Competitive Acid Blockers (PCABs). PCABs
act as K+ antagonists on the H+,K+-ATPase and their binding to the
pump from the lumenal side of the membrane is reversible. PCABs act
faster than PPIs as they do not require any activation. However,
because of their non-covalent binding to the H+,K+-ATPase, higher
doses are needed to produce an effect comparable to what is observed
with PPIs [59,60]. Nevertheless, if PCABs succeed in fulﬁlling the
requirements of clinical trials, they could constitute a new promising
class of pharmacological agents to treat gastric diseases. The last PCAB
to date, soraprazan, has already proved to be superior to PPIs in terms
of onset of action and complete control of acid secretion [62].Other inhibitors of the gastric H+,K+-ATPase include scopadulcic
acid B and its derivatives, which are antiviral agents against herpes
simplex virus type 1, and cibenzoline, a class I antiarrhytmic drug
[63,64]. Finally, prodigiosins are potent inhibitors of acid secretion and
they inhibit several types of proton-transporting pumps, including the
H+,K+-ATPase, through a chloride-dependent uncoupling mechanism
[65]. These antibiotics have also been shown to inhibit H. pylori
growth and could therefore constitute promising agents in the
treatment of gastroesophageal diseases.
3.3. SERCA inhibitors: controlling intracellular calcium concentration
In contrary to the Na+,K+- and the H+,K+-ATPases, no large family
of inhibitors has been deﬁned for SERCA. However, several
compounds and derivatives of high potency and selectivity have
been identiﬁed including thapsigargin, cyclopiazonic acid, and 2,5-di-
(t-butyl)-dihydroxybenzene. Thapsigargin is the most potent inhi-
bitor of SERCA described so far [38]. The natural product was
originally extracted from the plant Thapsia garganica which has been
used in Arabian medicine for more than 2000 years [66]. Several
studies demonstrated that thapsigargin can induce apoptosis in
different types of cancer cells [67,68]. Later it was shown that
programmed cell death is a direct consequence of an increase of the
intracellular calcium concentration due to the blocking of the SR/ER
Ca2+-ATPase. The steps following Ca2+-ATPase shut down by
thapsigargin have been further characterized by several groups (see
[17] for a review). First, a primary elevation of intracellular calcium
concentration is observed as a result of Ca2+ leakage by passive
diffusion from the ER stores. This primary raise stimulates the
translocation of several proteins to the plasma membrane, among
them the IP3R receptor and the annexin-V complex. This allows
increased inﬂux of calcium into the cytoplasm and leads to a second
elevation of the intracellular calcium that eventually activates
apoptotic factors and ﬁnally engages the cell death machinery [17].
Because thapsigargin will target all sarcoplasmic reticulum Ca2+-
ATPase pumps regardless of the cell type, its cytoxicity is too high to
consider it as a general antitumoral agent. However, a derivative that
selectively targets cancer cells would constitute a promising alter-
native to existing antitumoral drugs (such as paclitaxel, docetaxel,
doxorubicin), in particular for certain types of cancers which are
resistant to current therapies. Prostate cancer cells, contrary to most
cancer cells, are slowly growing and therefore hard to target by
conventional chemotherapy. Treatment of this type of cancer is a
typical example where synthesis of new drugs would be beneﬁcial.
The use of thapsigargin derivatives was therefore introduced as a
potential therapeutic tool to induce death of metastatic cells [17].
This new approach is based on the synthesis of inactive prodrugs
which contain a thapsigargin molecule coupled to a small peptide
carrier. Activation of the thapsigargin molecule requires the cleavage
of the peptide moiety by speciﬁc proteases. Therefore, one can
synthesize a tissue-speciﬁc drug by selecting a peptide which will
only be recognized by proteases of this cell type. Prostate cancer cells
produce such a speciﬁc protease and secrete it into the extracellular
ﬂuid. A thapsigargin-derived prodrug being a substrate for the
protease should consequently be cleaved in the vicinity of the
malignant cells. Complete validation of this strategy is still needed,
but it seems clear that more efforts will be put in this direction in the
future and this appealing approach could be extended to other
inhibitors of the Ca2+-ATPase [17].
Indeed, other inhibitors of SERCA have been proposed to have
therapeutic properties. Cyclopiazonic acid may have a cardioprotec-
tive action on myocardial ischemia [69]. How CPA inhibition of SERCA
could attenuate damages caused by oxygen deprivation is not fully
understood. But it is clear that modulation of the pump activity is
affecting the relaxing/contractile cycle of the heart muscle through
calcium ﬂux regulation.
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shown to inhibit SERCA to different degrees. The list includes
macrocyclin lactones such as cyclosporin A or rapamycin, which are
used as immunosuppressant agents, the anti-inﬂammatory drug
celecoxib, the antihelminthic agent ivermectin, the artiﬁcial estrogen
diethylstilbestrol, and curcumin derivatives [70–74]. Whether their
inhibition of the Ca2+-ATPase is part of their therapeutic response or is
just a secondary effect is however still unclear.
Finally, it was proposed that artemisinins (the most important
class of antimalarial drugs used today, which are sesquiterpene
lactones isolated from sweet wormwood Artemisia annua), could
inhibit the SERCA orthologue PfATP6 of Plasmodium falciparum, the
parasite causingmalaria [75]. Surprisingly, although these compounds
structurally resemble thapsigargin, they seem to have no effect on
mammalian SERCA pumps. It has been postulated that a single residue
in transmembrane helix TM3 near the thapsigargin pocket is
governing the selectivity of the pump for artemisinins [76]. Artemi-
sinins mode of action is however still controversial and some studies
suggested that they could act by haem-dependent activation of an
endoperoxide bridge occurring within the parasite's food vacuole
rather than by inhibition of PfATP6 [77].
4. The molecular mechanisms behind pump inhibition
Biochemical and structural studies on P-type ATPases inhibition
have so far been centred on a limited set of inhibitors with the highest
afﬁnity and the most immediate pharmacological interest. Intensive
mutagenesis studies have enabled to deﬁne more precisely the
binding pockets of several families of inhibitors, including the CTS
binding site on the extracellular side of the Na+,K+-ATPase and the PPI
and PCAB binding sites on the lumenal side of the H+,K+-ATPase. In the
case of SERCA, several crystallographic structures of the enzyme–
inhibitor complexes are now available and have enabled a precise
description of the mechanism by which these compounds affect the
enzyme's function. The new structures together have opened up forFig. 2. Visualization of the TG, CPA, BHQ and Boc12-ADT binding sites on SERCA. (A) General v
the E2·AlF4−–TG complex [22] (SERCA backbone and TGmolecule in blue), the E2·MgF42−-CPA c
(SERCA backbone and BHQ molecule in red) have been superimposed in O [140]. The gati
(represented in orange) is derived from the (Ca2)E1·AMPPCP state [21]whose transmembrane
(B) Binding pocket of CPA within the E2·MgF42−-CPA complex [29]. (C) Binding pocket of B
complex [22]. The three most important residues for TG binding (Phe256, Ile765 and Tyr837)possibilities of molecular modeling of inhibitor binding and for further
rational drug design attempts.
4.1. SERCA inhibitors: blocking the cytoplasmic pathway
In the absence of calcium, the detergent solubilized Ca2+-ATPase
enzyme from SR membranes is quite unstable and starts denaturing
rapidly [20]. Therefore, the E2 state of the pump has been a poor target
for crystallographic studies and attempts made so far to trap this
conformational state have largely failed although poorly diffracting
crystals have been reported [78]. However, it was shown that
inhibitors of SERCA favor an E2 conformation of the pump. They
were consequently used to stabilize this state and several E2 structures
of SERCA have been obtained in the presence of TG, CPA, BHQ, or
different combinations of these three inhibitors [20,22,23,27–29].
TG, CPA and BHQ all affect the Ca2+-ATPase pump cycle in a similar
way. They bind to the ATPase in a calcium-free state (referred to as E2–
P transition state, E2·Pi or E2) and act as Ca2+-antagonists on the
enzyme, preventing the binding of calcium ions from the cytoplasmic
side by blocking the pump in a conformational state which has very
low afﬁnity for calcium [79–81]. Due to these similarities in their
mode of action, these compounds were thought to share a common
mechanism of inhibition and consequently a common binding site on
the pump. However, structures of SERCA obtained in the presence of
these inhibitors revealed two distinct binding pockets, one pocket for
TG and one pocket for CPA and BHQ [27–29] (Fig. 2A). Moreover, both
binding pockets can be occupied by inhibitors at the same time
without affecting the respective afﬁnities for each compound and this
concomitant binding has even proved to further stabilize the E2 state
in crystallization experiments [27–28].
Several functional states have been crystallized in the presence of
these three inhibitors. Individual complexesof theCa2+-ATPasewithCPA,
BHQ, and TG have been obtained both in the E2·Pi (E2·MgF42−) and E2
states [20,23,27–29], and in the case of TG, the complex has also been
described in the E2·AlF4− state [22]mimicking the E2–P transition state ofiew of the inhibitors position in the transmembrane domain of SERCA. The structures of
omplex [29] (SERCA backbone and CPAmolecule in green) and the E2–BHQ complex [27]
ng residue Glu309 is shown in cyan as a stick representation. The cation binding site
regionhas been superimposed to the transmembrane region of the 3 other E2 structures.
HQ within the E2-BHQ complex [27]. (D) Binding pocket of TG within the E2·AlF4−–TG
are shown in red. (E) Binding pocket of Boc12-ADT within the E2·AlF4−–TG complex [84].
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positioning of each inhibitorwithin the so-far crystallized states, andwe
will for this reason mainly refer to only one state for each inhibitor.
Fig. 2A shows a general view of the binding sites of TG, CPA, and BHQ on
theCa2+-ATPasemolecule in the calcium-freeE2 (CPA [29] andBHQ[27])
or E2–P (TG) state [22]. The twodistinct cavities are clearly visible on the
structure. The TG binding cavity lies between transmembrane helices
TM3, TM4, TM5, and TM7, whereas the CPA/BHQ binding cavity
is formed by TM1, TM2, TM3, and TM4. CPA and BHQ binding sites
are only partially overlapping and the two molecules make speciﬁc
and distinct interactions with the surrounding residues [27–29].
Two different orientations of the CPA molecule have been described
within the binding pocket, one with the tetramic acid buried in a
hydrophobic pocket [28] and another with the tetramic acid facing the
surface [29] — clearly a matter of diverging interpretations of the same
structure that needs to be resolved. Still, the global occupancy of the
cavity remains the same and the overall conformation of the protein is
not affected within the two models. Therefore the conclusions
concerning the mechanism of inhibition that can be drawn from both
models have remained the same, although at least in one case they have
been based on incorrect arguments.
Fig. 2B and C shows a close-up view of the binding pockets for both
CPA and BHQ at the cytoplasmic cation access channel. In the
background, the cation binding sites from the (Ca2)E1·AMPPCP state
[21] are indicated in orange. Both inhibitors are clearly bound right in
the middle of the putative entry pathway for cytoplasmic calcium and
stabilize the E2 conformation of the transmembrane domain. Their
interactions with the surrounding residues also help pushing TM1 and
TM2 towards TM4, therefore slightly closing the access channel.
Moreover, the proposed gating residue Glu309 (shown in cyan in
FIG. 2) is blocked by the inhibitory molecule. Both CPA and BHQ are
located at sites close to TM4 and prevent the Glu309 side chain from
extending towards the entrance channel. The Glu309 residue can
therefore no longer act as a gating residue [27–29,82]. Thus, in short:
structures clearly show that the inhibitory effect of both CPA and BHQ
is based on the obstruction of the cytoplasmic access channel, which
consequently prevents calcium binding and the E2 to E1 transition.
While CPA and BHQ create a physical hindrance on the way of Ca2+
ions, TG has a distinct binding site (Fig. 2D) and therefore a unique
mode of inhibition. Its position in a cleft between TM3, TM5, and TM7
does not interfere directly with the cation access pathway. Rather, TG
immobilizes TM3, TM5, and TM7 in positions that are incompatible
with calcium binding. Indeed, mutagenesis studies have shown that
the main residues involved in TG binding are Phe256 (TM3), Ile765
(TM5), and Tyr837 (TM7) (Fig. 2D) [83]. These residues, and in
particular Phe256, undergo a large shift within the structure during
the E2 to (Ca2)E1 transition, due to the repositioning of the
transmembrane helices to accommodate the two calcium ions
[21,83]. Such a large movement is incompatible with the presence
of TG and the TG-bound protein is consequently trapped in a dead-
end complex which is almost irreversible due to the very high afﬁnity
binding of TG to the enzyme. Therefore, TG acts through a unique
mechanism on the Ca2+-ATPase by trapping it in a conformation that
prevents calcium re-entry without physically blocking the access
pathway.
In the search for TG analogs applicable in prostate cancer therapy,
several molecules were synthesized and tested for their ability to
inhibit SERCA [84]. In particular, a 12-Boc-aminododecaonoyl deriva-
tive (Boc12-ADT) was synthesized and co-crystallized with SERCA
[84]. Fig. 2E shows its position on the Ca2+-ATPase. The TGmain core of
the compound occupies the exact same pocket as the TG molecule
alone whereas the long 12-Boc-aminododecaonoyl tail extends right
through the protein and ends up at the cavity where CPA and BHQ
binding sites are located. This compound displays the same potency as
TG, probably because the network of interactions within the CPA/BHQ
cavity is not sufﬁcient to make new stabilizing contacts. It would seempossible to conjugate both modes of inhibition within a single
molecule to strengthen the inhibitory effect.
All three compounds (CPA, BHQ, and TG) have also been shown
to block the opening of the lumenal gate, hereby preventing the
reaction cycle from going backwards. Thus, even though they are
positioned deep within the membrane and near the cytoplasmic
access channel, these inhibitors also inﬂuence the lumenal exit
pathway [85].
It is not known if other inhibitors of SERCA act according to one of
the mechanisms described above. Nevertheless, several compounds
have been shown to stabilize E2 states and act as Ca2+-antagonists on
the Ca2+-ATPase (Fig. 1). 2-aminoethoxydiphenyl borate (2-APB),
which inhibits SERCA with an IC50 of 720±45 μM, binds to the pump
in a Ca-competitive manner, reducing the afﬁnity of the pump for
calcium by more than 20-fold [86]. It has been proposed that this
inhibitor could act in a way similar to TG and modeling studies have
identiﬁed the TG binding pocket as a putative site for 2-ABP
interaction with SERCA [84]. Xestospongin C, a SERCA inhibitor at
the vertebrate synapse, has been shown to compete with TG for the
binding to SERCA, suggesting that they could share a partially
overlapping binding site [87]. Finally, tetrabromobisphenol A, a potent
inhibitor of SERCA, yet used as a brominated ﬂame retardant, also
favours an E2 state of the enzyme and reduces its afﬁnity for calcium.
Competition experiments have suggested that it could share a
common binding site with BHQ [88].
4.2. Na+,K+-ATPase and cardiotonic steroid inhibitors: blocking the
extracellular pathway
Cardiotonic inhibitors (CTS) interact with the extracellular part of
the Na+,K+-ATPase. Despite their long tradition of use in cardiology,
the structural basis for their high afﬁnity binding towards the enzyme
remains elusive. The consequences of CTS binding for the binding
properties of other substrates of the Na+,K+-ATPase have been
subjected to kinetic investigations for many years [89–91]. However,
a complete understanding of the CTSmode of inhibition has up to now
been prevented by the absence of high-resolution 3D structure of the
Na+,K+-ATPase in complex with CTS— a structure which would allowa
description of the CTS–pump interaction at the atomic level. The
deﬁnition of the CTS binding pocket presents not only an academic
interest, it would be highly appreciated in drug design, advancing
synthesis of new highly potent and tissue-speciﬁc inhibitors.
Mutagenesis studies have implicated several residues in the
potential binding pocket for CTS on the Na+,K+-ATPase. Gln111 and
Asn122 in transmembrane helices TM1 and TM2 (residue numbering
corresponds to the pig renal α1 Na+,K+-ATPase sequence) were
identiﬁed as key residues for the interaction of the Na+,K+-ATPase
with CTS. Their change into respectively Arg and Asp is responsible
for the insensitivity of the rat and mouse Na+,K+-ATPase α1 isoforms
towards ouabain and analogs [92]. Subsequently, other residues
within the extracellular loops of the protein were involved in CTS
binding: Cys104, Tyr108, Pro118, Asp121, and Tyr124 in TM1 and TM2;
Tyr308, Leu330, Ala331, Thr338, and Cys367 in TM3 and TM4; Phe783,
Phe786, Leu793, and Thr797 in the TM5–TM6 loop; Phe863 and
Arg880 in the TM7–TM8 loop; and Phe982 in TM10 [93–97]. Finally,
using chimeras between the Na+,K+-ATPase and the gastric H+,K+-
ATPase, a subset of seven residues was found sufﬁcient to convert the
low-afﬁnity ouabain binding site of the gastric H+,K+-ATPase into a
binding site possessing the same high afﬁnity as native Na+,K+-ATPase:
Glu312, Val314, Ile315, Gly319, Phe783, Thr797, and Asp804 [98].
ThoughCTS canbind todifferent functional states of thepump, they
seem to favour the E2P conformation of the Na+,K+-ATPase [89–91].
Some of the mutations mentioned above therefore exert their effect
indirectly through a shift of a conformational equilibrium, e.g.
Phe786Leu, which increases the stability of the K+ bound form and,
thereby, the K+-ouabain antagonism [99]. By contrast, Phe783 seems to
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fold reduction in ouabain afﬁnity without any associated effect on K+
binding or conformational equilibria [97]. Application of solid state
NMR techniques for structural examination of the ouabain-binding site
of pig kidney Na+,K+-ATPase revealed that the steroid core of the
ouabain derivatives was more constrained than the sugar group [100].
It suggests that the steroid part establishes hydrogen bonds with the
amino acid residues, while the sugar faces away from the surface of the
protein. With the ﬁrst high-resolution structures of a P-type ATPase,
namely the Ca2+-ATPase [19–22], several attempts were made to dock
CTS on the extracellular side of a Na+,K+-ATPase model derived from
the SERCA structures [96,101]. Though bringing some useful informa-
tion, these models are lacking a high accuracy in their description of
the extracellular region because of the low level of sequence identity
between SERCA and the Na+,K+-ATPase in this region. Furthermore
these models were restricted by the use of occluded forms of SERCA as
startingmodels, possibly of small relevance to the conformational state
of CTS-bound forms. The recent ﬁrst structure of the Na+,K+-ATPase,
the pig renal α1β1γ complex in the [Rb2]E2·MgF42− occluded form
[25], is therefore a critical new source of information to create an
accuratemodel for the CTS binding on the Na+,K+-ATPase. Based on the
conformational changes of SERCA observed between the calcium-free
E2P state, obtained by an E2·BeF3− complex [24], and the occluded E2P
state, obtained by the E2·AlF4− [22] or E2·MgF42− form [28], we have
constructed an E2P model of the Na+,K+-ATPase and attempted by a
simple approach to manually place ouabain at its extracellular site
according to mutagenesis data (Fig. 3 — see legend for the description
of the model building and docking). As shown in Fig. 3A and B, in the
E2P conformation, the cation exit pathway is open towards the
extracellular side of the membrane. The cation binding site (visible at
the bottom of the entrance channel in orange) is now accessible to
extracellular K+. Because of this open conformation, a large cavity is
available at the top of the transmembrane region to accommodate
ouabain or other CTS with bulky glycosylations (Fig. 3B). The proposed
model of ouabain (Fig. 3C) binding positions the CTS molecule within
this cavity (Fig. 3D), in close proximity to residues that are shown to be
involved in ouabain binding (Fig. 3E), notably Gln111, Asn122, Tyr308,
and Glu312. The steroid core and the lactone moiety have been
positioned near TM1–TM2 and TM3–TM4, i.e. the residues affecting
CTS binding according to mutagenesis studies. However, a different
orientation of the ouabainmoleculewithin this cavity can not be ruled
out. Some of the residues in TM5–TM6, namely Phe783, Leu793, and
Thr797, shown to be very important for CTS binding in mutagenesis
studies, are a little too distant from the CTS molecule (approx. 5 Å) for
direct involvement in binding with in this model. It is however likely
that while the initial binding occurs in this open E2P conﬁguration a
further “induced ﬁt” rearrangement leads to a dead-end inhibited
complex in which TM5–TM6 has approached TM3–TM4, hereby
narrowing the cleft in which the CTS binds. It is also possible that the
large loop between TM7 and TM8 is rearranged upon ouabain binding
so that some residues, such as Arg880, may come in close contact with
the CTS molecule. The model suggests that the CTS molecule obstructs
the extracellular cation exit pathway, preventing K+ re-entry and
occlusion. Since CTS display a large variety in size, it is not certain that
all compounds would block the cation exit tunnel with the same
efﬁcacy. However, even a partial overlap could be sufﬁcient to block the
enzymatic cycle. Leu311 has for example been proposed to participate
in the cation gatingmechanism [102] and the position of ouabain in the
present model clearly interferes with this residue.
4.3. Gastric H+,K+-ATPase inhibitors: blocking the extracellular pathway
Omeprazole and derivatives (PPIs) are the main class of agents in
clinical use to treat peptic ulcers and GERD. Like CTS on the Na+,K+-
ATPase, they bind to the gastric H+,K+-ATPase in an E2P conformation
and act as cation antagonists. PPIs are sulphur-containing compoundsthat need to be converted into a reactive species, namely a cyclic
sulphenamide or a sulphenic acid, to be able to react with thiol groups
on the surface of their protein target [60]. This conversion is insured
by successive protonations of the PPImoleculewhich can only occur in
the very acidic environment of the lumen of the parietal cells (Fig. 4A).
Once activated, PPIs can form disulphide bonds with thiol groups on
the H+,K+-ATPase, forming a covalent complex with the pump which
in turn is irreversibly inhibited, forming a so-called suicide complex
[60]. Cross-linking and mutagenesis studies identiﬁed several
cysteines in the transmembrane region of the H+,K+-ATPase poten-
tially involved in PPI binding: Cys321, Cys813, Cys822, and Cys892
(residue numbering according to the human H+,K+-ATPase sequence)
[103,104]. Attempts to use molecular docking of the PPI molecule on
the H+,K+-ATPase lumenal surface have previously been presented
based on homology models of the H+,K+-ATPase using SERCA
structures as templates, however using other conformations than
the E2P-form and manual manipulations [105].
Here we propose a new homology model of the H+,K+-ATPase in
the E2P state based on the newly available structure of the Na+,K+-
ATPase [25] (Fig. 4B). Because of the high sequence identity between
the gastric H+,K+-ATPase and the Na+,K+-ATPase, this new model
enables a more precise localization of the cysteines possibly involved
in PPI binding (Fig. 4B and C). As shown in Fig. 4C, Cys813 appears as
the best candidate for PPI binding since it is lying at the end of helix
TM6, right in the middle of the lumenal cavity, at the exit of the cation
pathway. Mutagenesis studies also indicated that Cys813 could be the
predominant residue involved in PPI interaction since it binds to all
PPIs, whereas some other cysteines are PPI-speciﬁc (such as Cys822
which can crosslink with pantoprazole [60]). Mutagenesis studies
have been mainly focused on cysteine residues directly participating
in the covalent linking of PPIs and no other residues possibly
stabilizing the PPI molecule within its binding pocket have been
identiﬁed so far. Due to the formation of a covalently bound complex, a
docking model of PPIs on the H+,K+-ATPase is a quite challenging task,
and several different approaches have been investigated here in the
attempt to model the binding of omeprazole to the pump molecule.
Each of the activated forms of omeprazole, the sulphenic acid and the
cyclic sulphenamide, have been docked into the homology model of
the H+,K+-ATPase using the two isomeric structures shown in Fig. 4A,
reﬂecting the possible different placement of the methoxy group due
to stereochemical scrambling in the spiro-intermediate. Omeprazole
sulphide, a metabolite of omeprazole, has been shown to reduce the
inhibition of the H+,K+-ATPase by omeprazole and reduce the
omeprazole labelling of the pump [103]. However, the sulphide does
not inhibit the pump itself. It has therefore been suggested that this
compound competes with the activated form(s) of omeprazole for a
binding site on the pump prior to formation of the covalent bond
between the activated form of omeprazole and the protein [103]. To
investigate if a binding site for the protonated sulphide could give
some hints on the binding site for activated forms of omeprazole, this
compound has also been docked. The molecular docking attempts
resulted in a clear picture: all poses placing the sulphur atom of the
ligand in close proximity to the nucleophilic Cys813 have the
omeprazole-fragment binding behind helices TM1 and TM2. Fig. 4D
and E shows the two possible orientations of omeprazole in the
identiﬁed binding site within the lumenal side of the ATPase based on
the covalent docking calculations. The PPI molecule is located in the
groove that is just on top of the cation exit pathway towards the
lumenal side of the membrane. In this conﬁguration, PPIs would act
through the exact same mechanism as CTS on the Na+,K+-ATPase by
directly blocking the access of K+ ions to the cation binding site,
therefore trapping the H+,K+-ATPase in an inactive E2P state. A clear
preference in the docking poses generated is found for the model
displayed in Fig. 4E. In this model, omeprazole is covalently bound to
the Cys813 side chain placing the benzimidazole ring system behind
helices TM1 and TM2. The other identiﬁed binding mode for the
Fig. 3. Binding model of ouabain into an homology model of the E2P state of the pig renal Na+,K+-ATPase. To build the E2P homology model of the Na+,K+-ATPase, the structure of
the [Rb]2E2·MgF42− form of the \raster(100%,p)="ﬁgure3"pig renal Na+,K+ ATPase [25] was manually combined with the observed conformation of the Ca2+-ATPase in the open
E2·BeF3− form [24]. The invariant regions between these two E2 states were initially deduced by comparison of the Ca2+-ATPase structure in the E2·BeF3− and in the [H2–3]E2·AlF4−
forms using the program ESCET [139]. Of particular importance, the region consisting of the transmembrane helices TM6 to TM10 was found to be signiﬁcantly invariant. The
E2·BeF3− structure of the Ca2+-ATPase (representing the genuine E2P state) was then superimposed with the [Rb]2E2·MgF42− form of the Na+,K+-ATPase on the TM6 to TM10
invariant region. The transmembrane helices TM1–TM2 and TM3–TM4 and the A domain from the Na+,K+-ATPase were then superimposed on the Ca2+-ATPase E2·BeF3− structure
to impose the E2P state of the Na+,K+-ATPase (assuming a conserved mechanism of lumenal/extracellular opening in the E2P state). The connecting loop regions were manually
aligned in O [140]. (A) General view of the E2P model of the Na+,K+-ATPase. The approximate location of the membrane is indicated. (B) View of the transmembrane region of the
pig renal Na+,K+-ATPase in the E2P state from the extracellular side of the membrane. The cation binding site (positioned according to the [Rb]2E2·MgF42− structure [25]) is
visualized in orange down the open cation exit pathway. (C) Ouabain molecule. (D) Binding model of ouabain within the extracellular cavity on the surface of the Na+,K+-ATPase
E2P homology model. The ouabain molecule has been docked manually according to mutagenesis studies. The residues described as important for CTS binding are shown in light
yellow on the surface of the protein. (E) Same as D but with cartoons and sticks representations to visualize the possible interactions of residue side chains with the ouabain
molecule.
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of the two aromatic ring systems, placing the benzimidazole ring
near helix TM4. The inhibition mechanism of the two binding
modes will be the same, as the omeprazole-derivative sits in the
same binding pocket, only interchanging the two aromatic groups,
and effectively blocking the ion-transfer pathway. The inhibitory
mechanism may also be due to the possibility that omeprazole
bound in this cavity can obstruct the conformational changes
needed when going from E2P to E2·Pi. It is interesting to note that a
partly overlapping cavity has been proposed as the binding site for
PCABs, the other class of H+,K+-ATPase inhibitors [106].
More certain understanding of the mechanism of PPI inhibition
will require an atomic description of the inhibitor–pump complex
through high-resolution 3D structures combined with studies of the
dynamics and function of the protein. Nevertheless, all studies and
models proposed so far tend to conclude that PPIs, and possibly PCABs,
inhibit the H+,K+-ATPase by blocking the re-entry of K+ ions from the
lumenal side of the membrane, either by a direct obstruction of the
channel or by inducing conformational changes within the pump that
close the extracellular gate towards the stomach lumen.
4.4. Plasma membrane Ca2+- and H+-ATPases: autoinhibited pumps at
the cell surface
In addition to the above discussed Na+,K+- and H+,K+-ATPases, two
other P-type ATPases are localized in the plasma membrane, namely
the plasma membrane Ca2+-ATPase (P2B-type) and the plasma
membrane H+-ATPase (P3-type). Plasma membrane Ca2+-ATPases are
found in most eukaryotic cells where they serve important roles in
intracellular calcium regulation by being responsible for extrusion of
calcium from cells [107]. Plasma membrane H+-ATPases are restricted
to fungi and plants, where they are essential and function as
physiological analogs to the animal Na+,K+-ATPase by generating the
electrochemical gradients required for nutrient uptake through
secondary active transport systems [35].
Interestingly, P2B and P3 pumps share the same principle of
regulation. Typically, their cytoplasmically located carboxy-termini
are extended (although plant P2B-type ATPases have extended amino-
termini) and interact with the catalytic machinery of the pump to
down-regulate its activity in this way serving as built-in inhibitors.
Peptides have been designed that mimic the action of the auto-
inhibitory domains [108,109], but obviously such peptides have to act
from the cytoplasmic side of the membrane obscuring their
therapeutic potential. Peptides that bind to the autoinhibitory domain
have not been described yet, but it can be predicted that at least some
of these would act as pump activators.
A number of chemicals modulate the activity of P2B [110] and P3
[111–113] pumps, but in most cases their mechanism of action is from
the cytoplasmic side (e.g. eosin) or uncertain (e.g. juglone). Other lowFig. 4. Binding model of omeprazole into a homology model of the E2P state of the gastric H
in MODELLER [141] to generate a model of the E2P state of the human gastric H+,K+ ATPa
Energy (DOPE) score [142] was used for docking simulations with omeprazole. (A) Biochem
cause of accumulation of omeprazole in the lumen of the parietal cell, is protonation of
benzimidazole moiety which increases the electrophilicity of the C-2 carbon. A spiro interm
formed from the sulphenic acid by dehydration. Both the sulphenic acid and the sulphenam
The structure of omeprazole sulphide is also indicated. (B) General view of the E2P model of
the transmembrane region of the human gastric H+,K+-ATPase in the E2P state from the lum
according to crosslinking studies are shown as van der Waals representation. (D) and (E) Te
the H+,K+-ATPase E2P homology model created by covalent docking. The putative position o
ions within the Na+,K+-ATPase [Rb2]E2·MgF42− state [25]. The homology model was prepared
Suite (Schrödinger, LLC, New York; NY, 2007) and the ligands were drawn in Maestro 8.
structures were minimized with the MMFFs force ﬁeld as implemented in MacroModel 9.5 (
search was conducted using the Torsional Sampling, MCMM method in MacroModel 9.5. Mo
Inc (Schrödinger, LLC, New York; NY, 2007) using the SP scoring function [144]. The possibil
was also attempted. After covalent docking, a minimization (PRCG algorithm, 15,000 steps)
The majority of the generated poses for all compounds binds as shown in panel E. Struc
orientation of the protein is rotated approximately 90° compared to B. TM1 and TM2 are sho
in pink. For clarity, TM1 and TM2 are transparent. Only non-polar hydrogen atoms are shomolecular weight compounds target P2B and P3 pumps indirectly by
perturbing the lipid bilayer [114,115] or by interfering with the
regulatory machinery that controls auto-inhibition [116–118]. In
addition, fungal P3 pumps are targeted by compounds such as
omeprazole [119] and ebselen [120], which are unspeciﬁc in that
they also affect the gastric H+,K+-ATPase.
Screening of peptide libraries has become an interesting new
approach to design inhibitors that target P2B [121] and P3 [122]
ATPases from the cell surface. Cysteine bridge-constrained random
peptide libraries have been designed for isolation of peptides that bind
speciﬁcally to e.g. extracellular portions of plasma membrane Ca2+-
ATPase [123]. Peptide libraries with carboxy-terminal triarginine
motifs to concentrate library members at the fungal cell exterior have
been employed in case of the plasma membrane H+-ATPase [124].
Although the results of peptide-based approaches are still prelimin-
ary, promising new drug leads have been discovered this way and
await further studies.
5. Concluding remarks
The acknowledgement of P-type ATPases as versatile proteins has
increased the interest in their speciﬁc inhibitors in the last few years.
Regular papers on this subject were supplemented by reviews, but
each publication was devoted to one particular enzyme. Tadini-
Buoninsegni et al. [81] for example discussed in detail different
mechanisms of inhibition of Ca2+-ATPase, while Mijatovic et al. [125]
explored the applicability of cardiotonic steroids in cancer therapy.
The aim of the current publication is to summarize information about
the interactions between several representatives of the P-type ATPase
family with their respective inhibitors, deduced from the crystal-
lographic data, and to present some guidelines for the development of
the new generations of drugs, able to modulate (or shut down)
exclusively their target.
The high selectivity of the drug, i.e. its ability to bind to a particular
protein in a particular tissue, is crucial for its pharmacological
applicability. The problemwith CTSmedication is a perfect illustration
of this issue: despite their curative properties, their overall toxic
effects may lead to severe poisoning and eventual death of the
patients [126], limiting pharmacological use of cardiotonic steroids.
Thus, the major strategies for the design of inhibitors of such
important and wide-spread enzymes are: 1) synthesis of tissue (or
organ)-speciﬁc drugs; 2) development of isoform-speciﬁc drugs.
In the ﬁrst case a pro-drug is converted into an active form either
by speciﬁc environment or tissue-speciﬁc enzymes. This approach
has proven successful and resulted in the targeted delivery of
omeprazole and thapsigargin towards restricted pools of H+,K+-
ATPase and Ca2+-ATPase, respectively. Here the knowledge of
physiology and metabolism of the particular cells is decisive. In
addition, the structural data on the enzyme–inhibitor complex are+,K+-ATPase. The above E2P model of the Na+,K+ ATPase was used as template structure
se. Out of 100 models generated, the one with the lowest Discrete Optimized Protein
ical activation and inhibition mechanism of omeprazole. The ﬁrst step, which is the
the nitrogen atom in the pyridine moiety. Subsequently follows a protonation of the
ediate is then formed that collapses into the sulphenic acid. The cyclic sulphenamide is
ide can react with accessible thiols on the luminal surface of the H+,K+-ATPase [143].
the H+,K+-ATPase. The approximate location of the membrane is indicated. (C) View of
enal side of the membrane. The four cysteines possibly involved in the binding of PPIs
ntative binding models of omeprazole within the extracellular cavity on the surface of
f the cation binding site (shown in orange) is inferred from the position of the two K+
for docking calculations using the Protein Preparation Wizard in the Schrödinger 2007
0 (Schrödinger, LLC, New York; NY, 2007) with charges as indicated in panel A. The
Schrödinger, LLC, New York; NY, 2007). To localize the global minimum, a conformation
lecular docking simulations were performed using Glide version 4.5 from Schrodinger
ity of performing covalent docking in Prime 2.0 (Schrödinger, LLC, New York, NY, 2008)
was conducted using the OPLS2005 force ﬁeld [145,146] and an implicit water model.
tures shown in D and E are after minimization of the covalently docked poses. The
wn in purple; TM4 in green; TM5 and TM6 in brown; TM7 and TM8 in grey; and TM10
wn. All structures representations in this review have been drawn in PYMOL [147].
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induces minimal disturbances in the afﬁnity. The potentials of such
strategies in cancer treatment are evident.
The second approach is even more challenging. It implies that the
inhibitor interacts selectively with one isoform of the enzyme, leaving
the other molecules intact. No examples are known so far, because the
design of such an inhibitor demands a detailed knowledge of the
minute structural differences between isoforms.
The above strategies are applicable when the targeted enzyme has
a speciﬁc inhibitor. However, some of the P-type ATPases, being
potentially attractive drug targets, have no speciﬁc inhibitors or
modulators so far. In these cases, the homology between the enzymes
may be advantageous. It is obvious that the common transport
mechanism stipulates similar scaffolding of the enzymes. The recent
determination of the three-dimensional structures of the Na+,K+- and
H+-ATPases exhibited overall resemblance with the Ca2+-ATPase and
suggested that all P-type ATPases share a similar domain organization.
It is most likely that also the spatial position of the ion access channels
is conserved throughout the family. Binding of a substance within
these channels or in their vicinity will disturb ion binding (or the
conformational transitions following that binding) and, therefore,
interfere with the pump cycle. The crystallographic structures of the
enzyme–inhibitor complexes, as well as docking studies described in
this review, show that this is apparently a common mechanism of
inhibition of P-type ATPases. It seems also to be a rather efﬁcient way
of blocking the enzymes, specially for plasma membrane embedded
proteins, since the “pharmacological activity” of the inhibiting
substance does not depend on its ability to permeate the membrane.
Additionally, multidrug transporters, that often abolish the effect of
drugs by effectively extruding them from cells, cannot circumvent the
action of compounds that act from the outside of cells.
Crystallization of the enzyme of interest and detailed mapping of
its extracellular surface in order to ﬁnd a site for speciﬁc “wedging”
may be the ﬁrst step in the design of a new synthetic highly speciﬁc
inhibitor. This structure-based drug design strategy will compete with
the traditional drug screening schemes in terms of time and economic
costs. Constant development and standardization of the membrane
protein crystallization methods will turn the scale in favor of the
structural approach.
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